Healthcare providers beliefs about the meanings and impacts of prescription drug monitoring program alerts

References

• Allen B, Harocopos A, Chernick R. 2020. Substance use stigma, primary care, and the new york state prescription drug monitoring program. Behav Med. 46(1):52–62. doi: 10.1080/08964289.2018.1555129.
   PubMed Web of Science ®Google Scholar
• Alogaili F, Ghani NA, Shah NAK. 2020. Prescription drug monitoring programs in the US: a systematic literature review on its strength and weakness. J Infection Public Health. 13(10):1456–1461. doi: 10.1016/j.jiph.2020.06.035.
   PubMed Web of Science ®Google Scholar
• Antoniou T, Ala-Leppilampi K, Shearer D, Parsons JA, Tadrous M, Gomes T. 2019. ‘Like being put on an ice floe and shoved away’: a qualitative study of the impacts of opioid-related policy changes on people who take opioids. Int J Drug Policy. 66:15–22. doi: 10.1016/j.drugpo.2019.01.015.
   PubMed Web of Science ®Google Scholar
• Baker RG, Koroshetz WJ, Volkow ND. 2021. The helping to end addiction long-term (HEAL) Initiative of the National Institutes of Health. JAMA. 326(11):1005–1006. doi: 10.1001/jama.2021.13300.
   PubMed Web of Science ®Google Scholar
• Baldacchino A, Gilchrist G, Fleming R, Bannister J. 2010. Guilty until proven innocent: a qualitative study of the management of chronic non-cancer pain among patients with a history of substance abuse. Addict Behav. 35(3):270–272. doi: 10.1016/j.addbeh.2009.10.008.
   PubMed Web of Science ®Google Scholar
• Blum CJ, Nelson LS, Hoffman RS. 2016. A survey of physicians’ perspectives on the New York state mandatory prescription monitoring program (ISTOP). J Subs Abuse Treat. 70:35–43. doi: 10.1016/j.jsat.2016.07.013.
   PubMed Web of Science ®Google Scholar
• Braun V, Clarke V. 2006. Using thematic analysis in psychology. Qual Res Psychol. 3(2):77–101. doi: 10.1191/1478088706qp063oa.
   Google Scholar
• Buchman DZ, Ho A, Illes J. 2016. You present like a drug addict: patient and clinician perspectives on trust and trustworthiness in chronic pain management: table 1. Pain Med. 17(8):1394–1406. doi: 10.1093/pm/pnv083.
   PubMed Web of Science ®Google Scholar
• Burgess DJ, Van Ryn M, Crowley-Matoka M, Malat J. 2006. Understanding the provider contribution to race/ethnicity disparities in pain treatment: insights from dual process models of stereotyping. Pain Med. 7(2):119–134. doi: 10.1111/j.1526-4637.2006.00105.x.
   PubMed Web of Science ®Google Scholar
• Carter N, Bryant-Lukosius D, DiCenso A, Blythe J, Neville AJ. 2014. The use of triangulation in qualitative research. Oncol Nurs Forum. 41(5):545–547. PMID: 25158659. doi: 10.1188/14.ONF.545-547.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS. 2017. The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse. Dialogues Clin Neurosci. 19(3):259–269. doi: 10.31887/DCNS.2017.19.3/tcicero.
   PubMed Web of Science ®Google Scholar
• Cochran G, Brown J, Yu Z, Frede S, Bryan MA, Ferguson A, Bayyari N, Taylor B, Snyder ME, Charron E, et al. 2021. Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test. Drug Alcohol Depend. 228:109067. doi: 10.1016/j.drugalcdep.2021.109067.
   PubMed Web of Science ®Google Scholar
• Corrigan PW. 2000. Mental health stigma as social attribution: implications for research methods and attitude change. Clin Psychol Sci Practice. 7(1):48–67. doi: 10.1093/clipsy.7.1.48.
   Web of Science ®Google Scholar
• Corrigan PW, Watson AC, Miller FE. 2006. Blame, shame, and contamination: the impact of mental illness and drug dependence stigma on family members. J Fam Psychol. 20(2):239–246. doi: 10.1037/0893-3200.20.2.239.
   PubMed Web of Science ®Google Scholar
• Creswell J. 2014. Research design: qualatative, quantitaive and mixed methods approaches (4th ed.). Washington (DC), USA: Sage.
   Google Scholar
• Crouch M, McKenzie H. 2006. The logic of small samples in interview-based qualitative research. Social Science Information. 45(4):483–499. doi: 10.1177/0539018406069584.
   Web of Science ®Google Scholar
• Crowley-Matoka M, True G. 2012. NO ONE WANTS TO BE THE CANDY MAN: ambivalent medicalization and clinician subjectivity in pain management. Cult Anthropol. 27(4):689–712. doi: 10.1111/j.1548-1360.2012.01167.x.
   Web of Science ®Google Scholar
• Deloitte. 2018. Regulatory Impact Statement – Proposed Drugs, Poisons and Controlled Substances Amendment (Real-time Prescription Monitoring) Regulations 2018 (p. 73). Victoria, Australia: Victorian Government.
   Google Scholar
• Department of Health. 2019. SafeScript help topics https://help.safescript.vic.gov.au/release-notes/release-notes-2019-16.htm.
   Google Scholar
• Dowell D, Haegerich TM, Chou R. 2016. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. JAMA. 315(15):1624–1645. doi: 10.1001/jama.2016.1464.
   PubMed Web of Science ®Google Scholar
• Fendrich M, Bryan JK, Hooyer K. 2018. Prescription drug monitoring programs and pharmacist orientation toward dispensing controlled substances. Subst Use Misuse. 53(8):1324–1330. doi: 10.1080/10826084.2017.1408650.
   PubMed Web of Science ®Google Scholar
• Fink DS, Schleimer JP, Sarvet A, Grover KK, Delcher C, Castillo-Carniglia A, Kim JH, Rivera-Aguirre AE, Henry SG, Martins SS, et al. 2018. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Ann Internal Med. 168(11):783–790. doi: 10.7326/M17-3074.
   PubMed Web of Science ®Google Scholar
• FitzGerald C, Hurst S. 2017. Implicit bias in healthcare professionals: a systematic review. BMC Med Ethics. 18(1):19. doi: 10.1186/s12910-017-0179-8.
   PubMed Web of Science ®Google Scholar
• Green TC, Case P, Fiske H, Baird J, Cabral S, Burstein D, Schwartz V, Potter N, Walley AY, Bratberg J. 2017. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. J Am Pharm Assoc (2003). 57(2S):S19–S27.e4. doi: 10.1016/j.japh.2017.01.013.
   PubMed Web of Science ®Google Scholar
• Haines S, Savic M, Nielsen S, Carter A. 2022a. Key considerations for the implementation of clinically focused prescription drug monitoring programs to avoid unintended consequences. Int J Drug Policy. 101:103549. doi: 10.1016/j.drugpo.2021.103549.
   PubMed Web of Science ®Google Scholar
• Haines S, Lam A, Savic M, Carter A. 2022b. 2022. Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline. Int J Drug Policy. 109:103847. Epub Sep 5. PMID: 36067724. doi: 10.1016/j.drugpo.2022.103847.
   PubMedGoogle Scholar
• Haines S, Savic M, Nielsen S, Carter A. 2023c. Opioid-related policy changes: experiences and perspectives from people who use opioids to manage non-cancer chronic pain. Drug Alcohol Rev. 42(6):1482–1492. Epub ahead of print. PMID: 37254597. doi: 10.1111/dar.13683.
   PubMedGoogle Scholar
• Hildebran C, Leichtling G, Irvine JM, Cohen DJ, Hallvik SE, Deyo RA. 2016. Clinical styles and practice policies: influence on communication with patients regarding worrisome prescription drug monitoring program data: Table 1. Pain Med. 17(11):2061–2066. doi: 10.1093/pm/pnw019.
   PubMed Web of Science ®Google Scholar
• Holmgren AJ, Botelho A, Brandt AM. 2020. A history of prescription drug monitoring programs in the United States: political appeal and public health efficacy. Am J Public Health. 110(8):1191–1197. doi: 10.2105/AJPH.2020.305696.
   PubMed Web of Science ®Google Scholar
• Islam MM, McRae IS. 2014. An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. BMC Pharmacol Toxicol. 15(1):46. https://link.gale.com/apps/doc/A541266626/AONE?u=monash&sid=AONE&xid=0a44fd29. doi: 10.1186/2050-6511-15-46.
   PubMedGoogle Scholar
• James W. 1994. The physical basis of emotion. Psychol Rev. 101(2):205–210. doi: 10.1037/0033-295x.101.2.205.
   PubMed Web of Science ®Google Scholar
• Jayawardana S, Forman R, Johnston-Webber C, Campbell A, Berterame S, de Joncheere C, Aitken M, Mossialos E. 2021. Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study. EClinicalMedicine. 42:101198. doi: 10.1016/j.eclinm.2021.101198.
   PubMedGoogle Scholar
• Leichtling GJ, Irvine JM, Hildebran C, Cohen DJ, Hallvik SE, Deyo RA. 2017. Clinicians’ use of prescription drug monitoring programs in clinical practice and decision-making. Pain Med. 18(6):1063–1069. doi: 10.1093/pm/pnw251.
   PubMed Web of Science ®Google Scholar
• Lockton D, Harrison D, Stanton N. 2008. Design with intent: persuasive technology in a wider context. In H. Oinas-Kukkonen, P. Hasle, M. Harjumaa, K. Segerståhl, and P. Øhrstrøm, editors. Persuasive technology Vol. 5033, Berlin, Heidelberg: Springer. p. 274–278. doi: 10.1007/978-3-540-68504-3_30.
   Google Scholar
• Marcelin JR, Siraj DS, Victor R, Kotadia S, Maldonado YA. 2019. The impact of unconscious bias in healthcare: how to recognize and mitigate it. J Infect Dis. 220(Supplement_2):S62–S73. doi: 10.1093/infdis/jiz214.
   PubMedGoogle Scholar
• Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, Abdollahpour I, et al. 2020. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 396(10258):1223–1249. doi: 10.1016/S0140-6736(20)30752-2.
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Kilbourne EM, Desai HA. 2011. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 12(5):747–754. doi: 10.1111/j.1526-4637.2011.01062.x.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV, LeQuang JA. 2020. Reappraising the use of benzodiazepines in chronic pain patients. Postgraduate Med. 132(sup3):10–12. doi: 10.1080/00325481.2020.1725352.
   PubMedGoogle Scholar
• Picco L, Lam T, Haines S, Nielsen S. 2021. How prescription drug monitoring programs influence clinical decision-making: a mixed methods systematic review and meta-analysis. Drug Alcohol Depend. 228:109090. doi: 10.1016/j.drugalcdep.2021.109090.
   PubMed Web of Science ®Google Scholar
• Prochaska J, DiClemente C. 1983. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 51(3):390–395. doi: 10.1037/0022-006X.51.3.390.
   PubMed Web of Science ®Google Scholar
• Prochaska JO, Norcross JC. 1983. Transtheoretical therapy: toward a more integrative model of change. Psychother. 20(2):161–173. doi: 10.1037/h0088437.
   Google Scholar
• QSR International Pty Ltd. 2020. NVivo (released in March 2020), https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/home.
   Google Scholar
• Radomski TR, Bixler FR, Zickmund SL, Roman KM, Thorpe CT, Hale JA, Sileanu FE, Hausmann LRM, Thorpe JM, Suda KJ, et al. 2018. Physicians’ perspectives regarding prescription drug monitoring program use within the Department of Veterans Affairs: a multi-state qualitative study. J Gen Intern Med. 33(8):1253–1259. doi: 10.1007/s11606-018-4374-1.
   PubMed Web of Science ®Google Scholar
• Rhodes T, Closson EF, Paparini S, Guise A, Strathdee S. 2016. Towards ‘evidence-making intervention’ approaches in the social science of implementation science: the making of methadone in East Africa. Int J Drug Policy. 30:17–26. doi: 10.1016/j.drugpo.2016.01.002.
   PubMed Web of Science ®Google Scholar
• Smith SM, Allwright S, O’Dowd T. In The Cochrane Collaboration. 2007. Effectiveness of shared care across the interface between primary and specialty care in chronic disease management (Ed.), Cochrane Database of Systematic Reviews. Dublin, Ireland: John Wiley and Sons, Ltd. (p. CD004910). doi: 10.1002/14651858.CD004910.pub2.
   Google Scholar
• Teal CR, Gill AC, Green AR, Crandall S. 2012. Helping medical learners recognise and manage unconscious bias toward certain patient groups: education to reduce unconscious bias in medical learners. Med Educ. 46(1):80–88. doi: 10.1111/j.1365-2923.2011.04101.x.
   PubMed Web of Science ®Google Scholar
• Van Boekel LC, Brouwers EP, Van Weeghel J, Garretsen HF. 2013. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 131(1-2):23–35. doi: 10.1016/j.drugalcdep.2013.02.018.
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, et al. 2020. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 396(10258):1204–1222. doi: 10.1016/S0140-6736(20)30925-9.
   PubMed Web of Science ®Google Scholar
• Weiner B, Perry RP, Magnusson J. 1988. An attributional analysis of reactions to stigmas. J Personality Social Psychol. 55(5):738–748. doi: 10.1037/0022-3514.55.5.738.
   PubMed Web of Science ®Google Scholar
• Wilson J, Lam T, Scott D, Crossin R, Matthews S, Smith K, Lubman DI, Nielsen S. 2020. ‘Extreme personal stress’ and ‘a lot of pain’: Exploring the physical, mental and social contexts of extramedical pharmaceutical opioid use in Australian paramedic case descriptions. Drug Alcohol Rev. 39(7):870–878. doi: 10.1111/dar.13118.
   PubMed Web of Science ®Google Scholar
• Wilson MN, Hayden JA, Rhodes E, Robinson A, Asbridge M. 2019. Effectiveness of prescription monitoring programs in reducing opioid prescribing, dispensing, and use outcomes: a systematic review. J Pain. 20(12):1383–1393. doi: 10.1016/j.jpain.2019.04.007.
   PubMed Web of Science ®Google Scholar